Renee Gala

Ms. Gala brings more than 30 years of experience across finance, strategy, corporate development and commercialization. Ms. Gala became president and chief executive officer in August 2025. She previously served as Jazz’s chief operating officer overseeing the company’s global business operations, which include commercial, medical, research and development, technical operations and quality, as well as corporate strategy. Ms. Gala previously served as Jazz’s chief financial officer beginning in 2020 and took on the role of chief operating officer in 2023. Ms. Gala is a passionate proponent of improving diversity within the healthcare industry.

Prior to joining Jazz in 2020, Ms. Gala served as the chief financial officer of GRAIL Inc., a healthcare company focused on early cancer detection. From 2014 to 2019, she served as senior vice president and chief financial officer of Theravance Biopharma, Inc., a biopharmaceutical company, following its spin-out from Theravance, Inc. (now INVA). Ms. Gala joined Theravance in 2006 and held various roles in the finance organization before leading the company’s spin-out transaction. Prior to that, Ms. Gala served in various roles in global treasury, pharmaceutical sales and corporate strategy/business development at Eli Lilly and Company from 2001 to 2006. Before joining Eli Lilly, Ms. Gala spent seven years in the energy industry in positions focused on corporate finance, project finance, and mergers and acquisitions. Ms. Gala currently serves on the board of Dexcom and has previously served on the board of multiple biotech companies, including Gossamer Bio, Gyroscope Therapeutics (acquired by Novartis) and Corcept Therapeutics. Ms. Gala holds a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School.